Payment overview · 2025
General Payments
$949.38
47 reported records · 15 companies
Healthcare provider profile · identity verified
Robert Francis Schaefer, MD
Allopathic & Osteopathic Physicians|Family Medicine · HIGHLAND, IL · NPI 1659481299
Verified facts
What the public records show
CMS Open Payments records show Robert Francis Schaefer, MD received $949.38 in general payments during 2025 across 47 reported records.
ABBVIE INC. accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 390 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $167.65 | 17.7% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.16 | 15.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.27 | 11.0% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $98.95 | 10.4% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.88 | 8.7% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $77.08 | 8.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $66.36 | 7.0% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $45.34 | 4.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.17 | 3.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.72 | 3.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.66 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.72 | 1.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $16.34 | 1.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.19 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.89 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $872.30 | 45 |
| Education | $77.08 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $143.44 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $135.44 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $132.78 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $118.06 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.27 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $85.27 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.88 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.48 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $73.22 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $73.22 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $68.07 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $59.64 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.30 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $45.34 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.36 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.36 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 49 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 118 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
111 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 30 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
390 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1076 | 270 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 934 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 723 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 701 | 181 |
| Lisinopril | Lisinopril | 581 | 156 |
| Gabapentin | Gabapentin | 575 | 140 |
| Omeprazole | Omeprazole | 525 | 142 |
| Metformin Hcl | Metformin Hcl | 460 | 119 |
| Eliquis | Apixaban | 390 | 50 |
| Furosemide | Furosemide | 351 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 347 | 91 |
| Tramadol Hcl | Tramadol Hcl | 341 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 339 | 102 |
| Losartan Potassium | Losartan Potassium | 326 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 320 | 84 |
| Potassium Chloride | Potassium Chloride | 304 | 66 |
| Sertraline Hcl | Sertraline Hcl | 303 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 300 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 100 |
| Hydrochlorothiazide | Hydrochlorothiazide | 276 | 72 |
| Trazodone Hcl | Trazodone Hcl | 276 | 68 |
| Simvastatin | Simvastatin | 246 | 64 |
| Allopurinol | Allopurinol | 224 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 224 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 57 |
| Meloxicam | Meloxicam | 208 | 60 |
| Carvedilol | Carvedilol | 193 | 51 |
| Alprazolam | Alprazolam | 189 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 189 | 36 |
| Buspirone Hcl | Buspirone Hcl | 186 | 51 |
| Montelukast Sodium | Montelukast Sodium | 182 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 176 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 173 | 45 |
| Donepezil Hcl | Donepezil Hcl | 172 | 34 |
| Lorazepam | Lorazepam | 157 | 29 |
| Metformin Hcl Er | Metformin Hcl | 157 | 40 |
| Mirtazapine | Mirtazapine | 156 | 37 |
| Prednisone | Prednisone | 152 | 98 |
| Famotidine | Famotidine | 151 | 42 |
| Cephalexin | Cephalexin | 140 | 52 |
| Pregabalin | Pregabalin | 139 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 130 | 18 |
| Spironolactone | Spironolactone | 123 | 26 |
| Finasteride | Finasteride | 122 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 30 |
| Jardiance | Empagliflozin | 118 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 40 |
| Methocarbamol | Methocarbamol | 115 | 37 |
| Ondansetron Hcl | Ondansetron Hcl | 114 | 34 |
| Baclofen | Baclofen | 112 | 19 |
| Glimepiride | Glimepiride | 112 | 27 |
| Myrbetriq | Mirabegron | 111 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 105 | 25 |
| Ozempic | Semaglutide | 100 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 34 |
| Ezetimibe | Ezetimibe | 93 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 91 | 25 |
| Levetiracetam | Levetiracetam | 90 | 18 |
| Lovastatin | Lovastatin | 90 | 17 |
| Glipizide | Glipizide | 87 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 83 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 25 |
| Warfarin Sodium | Warfarin Sodium | 83 | 14 |
| Xarelto | Rivaroxaban | 83 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 19 |
| Meclizine Hcl | Meclizine Hcl | 77 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 13 |
| Bupropion Xl | Bupropion Hcl | 74 | 18 |
| Sucralfate | Sucralfate | 74 | 13 |
| Gemfibrozil | Gemfibrozil | 72 | 29 |
| Clonazepam | Clonazepam | 71 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 15 |
| Azithromycin | Azithromycin | 70 | 53 |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 17 |
| Ibuprofen | Ibuprofen | 69 | 12 |
| Memantine Hcl | Memantine Hcl | 65 | 16 |
| Fenofibrate | Fenofibrate | 64 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 62 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 12 |
| Trulicity | Dulaglutide | 61 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 12 |
| Ondansetron Odt | Ondansetron | 53 | 14 |
| Topiramate | Topiramate | 50 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 50 | 16 |
| Alendronate Sodium | Alendronate Sodium | 49 | 18 |
| Farxiga | Dapagliflozin Propanediol | 49 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 48 | 12 |
| Atenolol | Atenolol | 48 | 15 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Vascepa | Icosapent Ethyl | 47 | 11 |
| Celecoxib | Celecoxib | 45 | 12 |
| Divalproex Sodium | Divalproex Sodium | 45 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 43 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 42 | 12 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Nystatin | Nystatin | 40 | 24 |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 17 |
| Primidone | Primidone | 37 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 36 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 36 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 16 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 33 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 27 |
| Brilinta | Ticagrelor | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 25 |
| Diazepam | Diazepam | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 14 |
| Fentanyl | Fentanyl | 29 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 14 |
| Latanoprost | Latanoprost | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Leflunomide | Leflunomide | 23 | suppressed |
| Nyamyc | Nystatin | 23 | 11 |
| Tradjenta | Linagliptin | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 20 |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | 13 |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 11 |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 17 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Azathioprine | Azathioprine | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fluocinonide-E | Fluocinonide/Emollient Base | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Phenytoin | Phenytoin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $949.38 · 47 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, UBRELVY, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error